HIV/AIDS Archives - Infectious Disease Advisor

CROI 2020

Raltegravir-Based ART Shows Lower Rates of Hepatoxicity

By

Zahra Masoud

April 3, 2020

Replacing efavirenz (EFV) with raltegravir (RAL) in antiretroviral therapy (ART) may decrease hepatotoxicity in patients who are coinfected with HIV and hepatitis C virus (HCV).

CROI 2020

CMV-Specific Immune Response in Advanced HIV Infections

By

Bradley van Paridon

April 2, 2020

Cytomegalovirus (CMV) viremia is suppressed after the start of antiretroviral treatment (ART) without specific anti-CMV treatment.

CROI 2020

Two-Drug Regimens Comparable With Three-Drug Regimens for HIV

By

Dibash Das, PhD

April 2, 2020

Two-drug regimens are shown to be comparable with 3-drug regimens as viable clinical treatment options for HIV.

CROI 2020

Discontinuation of Dolutegravir Due to Neurologic Side Effects Linked to Pre-Existing Mental Illness

By

Zahra Masoud

April 1, 2020

Dolutegravir (DTG) discontinuation due to neuropsychologic side effects (NPS) may be associated with pre-existing psychiatric conditions of depression and anxiety.

HIV/AIDS

Mood Disorders With HIV Increase Risk for Noncommunicable Disease

By

Zahra Masoud

March 31, 2020

Focused prevention and treatment of noncommunicable diseases may reduce the burden of multimorbidity in people living with HIV who have mood disorders and multimorbidity.

After diagnosis in the HIV care continuum is LTC. The CDC and Institute of Medicine (IOM) define LTC as “a period of 3 months or less between documentation of diagnosis and initiation of medical treatment with an HIV care provider/prescriber.”1 The 3-month benchmark was established because data show PLWH who start ART in the first 3 months after diagnosis achieve viral suppression faster than PLWH who delay treatment.1 Despite the critical importance of early ART, only 59% to 80% of PLWH in the United States start HIV care within 3 months of diagnosis.1 Although other high-income countries report higher LTC rates than the United States, their data show that having access to care does not guarantee patients will receive care. Various strategies have been proposed to promote LTC specifically in populations less likely to be linked to care, including drug users and low-income PLWH. Facilitating LTC may require an interdisciplinary team spread among multiple facilities.

CROI 2020

Long-Acting Cabotegravir + Rilpivirine Noninferior to Standard Treatment for HIV

By

Zahra Masoud

March 31, 2020

A long-acting therapy may be noninferior to the current daily oral antiretroviral therapy (ART) in maintaining viral suppression in the treatment of HIV-1 infection.